Abeona Therapeutics (ABEO) EBITDA (2011 - 2026)

Abeona Therapeutics' EBITDA history runs 16 years deep, the most recent figure standing at -$23.0 million for Q1 2026.

• On a quarterly basis, EBITDA fell 16.76% year-over-year to -$23.0 million in Q1 2026; TTM through Mar 2026 was -$92.8 million, a 33.25% decrease from a year earlier, with the FY2025 full-year figure at -$89.4 million, down 39.3% from the prior year.
• EBITDA eased to -$23.0 million in Q1 2026 per ABEO's latest filing, from -$22.9 million in the prior quarter.
• Across five years, EBITDA topped out at -$8.0 million in Q2 2022 and bottomed at -$24.0 million in Q3 2025.
• The 5-year median for EBITDA is -$15.3 million (2024), against an average of -$16.2 million.
• Across the five-year window, EBITDA soared 72.27% in 2022 and tumbled 69.26% in 2024, its largest moves.
• Year by year, EBITDA stood at -$12.9 million in 2022, then declined by 2.11% to -$13.2 million in 2023, then declined by 26.22% to -$16.7 million in 2024, then sank by 37.42% to -$22.9 million in 2025, then slipped by 0.53% to -$23.0 million in 2026.
• Per Business Quant, the three latest ABEO EBITDA figures stand at -$23.0 million (Q1 2026), -$22.9 million (Q4 2025), and -$24.0 million (Q3 2025).